MannKind Corporation (NASDAQ:MNKD) surged 9.22%, rising again seemingly on optimism that the company is targeting a large unmet need in the ever-expanding diabetes space and its main focus is on its wonder-drug: AFREZZA. Some may be hopeful that AFREZZA is going to become the dominant player in the $44B insulin market due to its unique pharmacokinetics/efficacy and convenience.
In addition, a SA contributor recently suggested investors the stock has been completely overlooked, and as a result, is severely undervalued.
Looking at an upcoming catalyst, the company is set to present at the J.P. Morgan 2014 Healthcare Conference on Wednesday, January 15, 2014 at 7:30 AM (PST) at Westin St. Francis Hotel in San Francisco, California.
ArthroCare Corporation (NASDAQ:ARTC) advanced 14.76% to more than 5-year high on news that the company and the U.S. Department of Justice (“DOJ”) entered into a Deferred Prosecution Agreement (“DPA”) filed yesterday with the United States District Court in the Western District of Texas (the Court). The DPA is expected to resolve the ongoing investigation by the DOJ regarding allegations of securities and related fraud committed under a previous management team.